On February 28, 2023, Dr. Gregory M. Glenn, M.D. notified Novavax Inc. of his decision to retire as President, Research and Development, effective as of March 31, 2023. The Company intends to retain Dr. Glenn as the Company's Strategic Research & Development Advisor, providing consulting services to the Company following his retirement.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.7 USD | +5.30% | +21.71% | +227.08% |
May. 21 | Novavax: 1st shipment of R21/MatrixM malaria vaccine | CF |
May. 20 | Global markets live: Apple, Tesla, Pfizer, AstraZeneca, Microsoft... |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+227.08% | 2.2B | |
+64.23% | 62.59B | |
-2.31% | 41.18B | |
+44.02% | 40.29B | |
-8.29% | 27.9B | |
+11.97% | 26.21B | |
-21.16% | 19.09B | |
+7.54% | 13.08B | |
+27.17% | 12.05B | |
+25.72% | 12.26B |
- Stock Market
- Equities
- NVAX Stock
- News Novavax, Inc.
- Novavax Inc. Announces the Retirement of Gregory M. Glenn, M.D. as President, Research and Development, Effective as of March 31, 2023